ARK Genomic Revolution ETF (BATS:ARKG) Shares Sold by Bellecapital International Ltd.

Bellecapital International Ltd. decreased its holdings in shares of ARK Genomic Revolution ETF (BATS:ARKG) by 1.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 73,583 shares of the company’s stock after selling 1,250 shares during the quarter. Bellecapital International Ltd. owned about 0.13% of ARK Genomic Revolution ETF worth $1,884,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in ARKG. EverSource Wealth Advisors LLC acquired a new stake in ARK Genomic Revolution ETF in the first quarter worth $49,000. Park Avenue Securities LLC increased its holdings in shares of ARK Genomic Revolution ETF by 14.0% in the 1st quarter. Park Avenue Securities LLC now owns 11,667 shares of the company’s stock valued at $336,000 after purchasing an additional 1,435 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of ARK Genomic Revolution ETF by 271.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 642,800 shares of the company’s stock valued at $21,090,000 after buying an additional 469,740 shares during the period. Cetera Investment Advisers boosted its position in ARK Genomic Revolution ETF by 290.7% during the first quarter. Cetera Investment Advisers now owns 140,897 shares of the company’s stock valued at $4,052,000 after purchasing an additional 104,831 shares during the last quarter. Finally, Janney Montgomery Scott LLC lifted its holdings in shares of ARK Genomic Revolution ETF by 14.2% during the 1st quarter. Janney Montgomery Scott LLC now owns 8,425 shares of the company’s stock valued at $242,000 after buying an additional 1,045 shares during the last quarter.

ARK Genomic Revolution ETF Trading Up 1.8 %

Shares of ARKG stock traded up $0.45 on Monday, hitting $24.78. The company’s stock had a trading volume of 840,414 shares. The firm’s fifty day moving average price is $25.45 and its two-hundred day moving average price is $25.24.

ARK Genomic Revolution ETF Company Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.